Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2005

01-08-2005

Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor α and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure

Authors: Dirk J. Grünhagen, MD, Boudewijn van Etten, MD, Flavia Brunstein, MD, Wilfried J. Graveland, MSc, Albertus N. van Geel, MD, PhD, Johannes H. W. de Wilt, MD, PhD, Alexander M. M. Eggermont, MD, PhD

Published in: Annals of Surgical Oncology | Issue 8/2005

Login to get access

Abstract

Background

Isolated limb perfusion (ILP) is an effective treatment modality for multiple in-transit melanoma metastases confined to the limb. Recurrences after ILP, however, occur in approximately 50% of patients and are a challenge for further treatment. The efficacy of repeat ILPs to prolong local control in this patient category is evaluated in this article.

Methods

We used a prospective database in a tertiary referral center. Out of 100 tumor necrosis factor (TNF)-based ILPs with TNF and melphalan (TM-ILPs) in melanoma patients between March 1991 and July 2003, 25 repeat ILP procedures were performed in 21 patients in whom prior ILP treatment failed. All patients had bulky and/or numerous lesions and were treated with mild hyperthermic TM-ILP by using 2 to 4 mg of TNF and 10 to 13 mg/L of limb volume for the leg and arm, respectively.

Results

The complete response rate was 76%, a partial response occurred in 20%, and no change was recorded in 4%. There was no difference in the complete response rate or local toxicity between first and repeat perfusions. Local recurrence occurred in 72%; the median time to local progression was 14 months. The 5-year survival rate was 47%, which compares favorably with known survival rates of stage IIIA/AB patients. The median follow-up of the patients was 26 months.

Conclusions

Patients who experience treatment failure after previous ILP treatment respond very well to repeat perfusion, and prolonged local control can thus be obtained. The subgroup of patients qualifying for repeat ILP represents a relatively favorable biological behavior of the melanoma.
Literature
1.
Eggermont AM. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 1996;26:335–49
2.
Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52–60
3.
Lejeune F, Lienard D, Eggermont A, et al. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J Cell Biochem 1994;56:52–61
4.
Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622–34
5.
Grünhagen DJ, Brunstein F, Graveland WJ, et al. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004;240:939–48
6.
Klop WM, Vrouenraets BC, van Geel BN, et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg 1996;182:467–72
7.
Bartlett DL, Ma G, Alexander HR, et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997;80:2084–90
8.
Feldman AL, Alexander HR Jr, Bartlett DL, et al. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 1999;6:562–7
9.
Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756–64; discussion 764–5
10.
Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14:2653–65
11.
Klaase JM, Kroon BB, van Geel AN, et al. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993;80:1124–6
12.
Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905–10
13.
WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization, 1979
14.
Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997;132:903–7
15.
Polk HC Jr, Edwards MJ. Post-perfusion recurrent melanoma. Ann Surg Oncol 1999;6:524
16.
de Wilt JH, ten Hagen TL, de Boeck G, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000–3
17.
de Wilt JH, Manusama ER, van Tiel ST, et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999;80:161–6
18.
Stam TC, Swaak AJ, de Vries MR, et al. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol 2000;7:268–75
19.
Vrouenraets BC, Kroon BB, Ogilvie AC, et al. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 1999;6:405–12
20.
van Etten B, van Geel AN, de Wilt JH, Eggermont AM. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 2003;10:32–7
Metadata
Title
Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor α and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure
Authors
Dirk J. Grünhagen, MD
Boudewijn van Etten, MD
Flavia Brunstein, MD
Wilfried J. Graveland, MSc
Albertus N. van Geel, MD, PhD
Johannes H. W. de Wilt, MD, PhD
Alexander M. M. Eggermont, MD, PhD
Publication date
01-08-2005
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 8/2005
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2005.03.060

Other articles of this Issue 8/2005

Annals of Surgical Oncology 8/2005 Go to the issue

OriginalPaper

Predicting Nonsentinel Node Status After Positive Sentinel Lymph Biopsy for Breast Cancer: Clinicians Versus Nomogram

OriginalPaper

Preoperative Chemoradiotherapy (Modified Eilber Protocol) Provides Maximum Local Control and Minimal Morbidity in Patients With Soft Tissue Sarcoma

Editorial

What Is the Best Treatment for Stage IV Colorectal Cancer?

Editorial

In-Transit Recurrence After Sentinel Lymph NodeBiopsy in Melanoma: Primum Non Nocere

OriginalPaper

Surgical Resection of Primary Tumors in Patients Who Present With Stage IV Colorectal Cancer: An Analysis of Surveillance, Epidemiology, and End Results Data, 1988 to 2000

OriginalPaper

Predictors and Natural History of In-Transit Melanoma After Sentinel Lymphadenectomy